Trials / Completed
CompletedNCT05173792
Study of AK119 in Subjects With Advanced Solid Tumors
A Phase I, Multicenter, Open-Label, Dose-escalation and Dose-exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of of AK119 (CD73) in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK119 | Subjects will receive AK119 intravenously. |
Timeline
- Start date
- 2021-12-22
- Primary completion
- 2023-05-22
- Completion
- 2023-05-22
- First posted
- 2021-12-30
- Last updated
- 2024-04-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05173792. Inclusion in this directory is not an endorsement.